Skip to main content
Premium Trial:

Request an Annual Quote

Boys, Too


Human papillomavirus is known to cause cervical cancer, but researchers have also linked it throat cancer, and there is evidence to suggest that it can cause other cancers as well. Until now, the available HPV vaccines have only been given to women and girls. But a US federal advisory committee has said that boys and young men should be vaccinated to protect against anal and throat cancers, reports The New York Times' Gardiner Harris. The Centers for Disease Control and Prevention's immunization advisory committee says boys aged 11 through 21 should be vaccinated, though the vaccine can also be given to boys as young as nine and men between the ages of 22 and 26. The vaccine has caused some political controversy, but experts are adamant about its positive effects. "This is cancer, for Pete's sake," Vanderbilt University School of Medicine's William Schaffner tells Harris. "A vaccine against cancer was the dream of our youth." The committee's recommendations are likely to cause private insurers to begin paying for boys to receive the vaccine, Harris adds.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.